Published • loading... • Updated
Moderna Has Doubled in 2026 — But Wall Street Is Not Buying the Rally
Summary by pcdn.co
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Moderna Has Doubled in 2026 — But Wall Street Is Not Buying the Rally
Moderna (NASDAQ: MRNA) shares have surged more than 100% in 2026, with the stock recently touching 52-week highs above $81 per share. But Wall Street analysts are nowhere close to endorsing the move. The consensus rating on MRNA sits at “Reduce,” with an average 12-month price target of around $38 to $49 — roughly 40% to 50% below where the stock is trading today. That disconnect between price performance and analyst conviction makes Moderna one…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
